Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Operating Expenses (2016 - 2026)

Ironwood Pharmaceuticals' Operating Expenses history spans 16 years, with the latest figure at $40.9 million for Q4 2025.

  • On a quarterly basis, Operating Expenses fell 30.73% to $40.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $197.6 million, a 23.48% decrease, with the full-year FY2025 number at $197.6 million, down 23.48% from a year prior.
  • Operating Expenses hit $40.9 million in Q4 2025 for Ironwood Pharmaceuticals, down from $46.6 million in the prior quarter.
  • Over the last five years, Operating Expenses for IRWD hit a ceiling of $1.2 billion in Q2 2023 and a floor of $38.6 million in Q3 2021.
  • Historically, Operating Expenses has averaged $109.3 million across 5 years, with a median of $45.3 million in 2023.
  • Biggest five-year swings in Operating Expenses: surged 2763.48% in 2023 and later crashed 94.17% in 2024.
  • Tracing IRWD's Operating Expenses over 5 years: stood at $60.5 million in 2021, then crashed by 35.85% to $38.8 million in 2022, then skyrocketed by 105.9% to $80.0 million in 2023, then fell by 26.15% to $59.1 million in 2024, then plummeted by 30.73% to $40.9 million in 2025.
  • Business Quant data shows Operating Expenses for IRWD at $40.9 million in Q4 2025, $46.6 million in Q3 2025, and $39.9 million in Q2 2025.